Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary immune thrombocytopenia (ITP) is rare. First-line treatment is corticotherapy. Then, several second-line treatments (SLT) are available: splenectomy, off-label rituximab and thrombopoietin-receptor agonists since 2009. The compared efficacy and safety on clinical events in the long-term are unknown. The main objective of the FAITH study is to build the cohort of all treated adult persistent (≥3 months) primary ITP patients in France, to assess the benefit-to-risk ratio of SLT in real-life practice. Data source is the database of French Health Insurance System (SNIIRAM) which covers the entire French population. It collects demographic, chronic disease, hospitalization and drug dispensing data. All patients with ITP were extracted from 2009 to 2012, and then every year for 10 years. The investigator will build the cohort from raw data. Outcomes (death, hospitalization, drug dispensing) will be compared according to SLT, with controls from the general population and untreated patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort | Data to be collected are : - Medical information on Immune Thrombocytopenia treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Medical information | Other | The information collected are about :
|
| Measure | Description | Time Frame |
|---|---|---|
| Exposition or non exposition to available immune thrombocytopenia persistent | Data will be extracted until the end of study | up to 10 years |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality as assessed date of death collected in the database | Data will be extracted every year of the study until the end of study | Each year until 10 years |
| Number of hospitalization for bleeding in the database |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Population of patient registred in national administrative french database
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Maryse LAPEYRE-MESTRE, PHD | Contact | maryse.lapeyre-mestre@univ-tlse3.fr |
| Name | Affiliation | Role |
|---|---|---|
| Maryse LAPEYRE-MESTRE, PHD | University Hospital of Toulouse | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Toulouse | Recruiting | Toulouse | 31059 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013921 | Thrombocytopenia |
| ID | Term |
|---|---|
| D001791 | Blood Platelet Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D000095542 | Cytopenia |
Not provided
Not provided
Not provided
Not provided
Not provided
Number of hospitalization for bleeding will be extract from database every year
| Each year until 10 years |
| Safety of treatment for infections | Number of infections is represented by number of hospitalization and antibiotics dispensation and will be extract from database every year | Each year until 10 years |
| Safety of treatment for cardio-vascular events | Number of hospitalization for cardio-vascular events will be extract from database every year | Each year until 10 years |
| Safety of treatment for thrombo-embolic events | Number of hospitalization for thrombo-embolic events will be extract from database every year | Each year until 10 years |